| 臺大學術典藏 |
2021-07-03T03:34:46Z |
Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
|
Hsu C.-H.; Yang T.-S.; Hsu C.; Toh H.C.; Epstein R.J.; Hsiao L.-T.; PEI-JER CHEN; Lin Z.-Z.; Chao T.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2021-07-03T03:34:45Z |
Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: Experts'opinion
|
PEI-JER CHEN; Furuse J.; Han K.-H.; Hsu C.; Lim H.-Y.; Moon H.; Qin S.; Ye S.-L.; Yeoh E.-M.; Yeo W. |
| 臺大學術典藏 |
2021-07-03T03:34:40Z |
Eastern asian expert panel opinion: Designing clinical trials of molecular targeted therapy for hepatocellular carcinoma
|
Yeo W.; PEI-JER CHEN; Furuse J.; Han K.-H.; Hsu C.; Lim H.-Y.; Moon H.; Qin S.; Yeoh E.-M.; Ye S.-L. |
| 臺大學術典藏 |
2021-07-03T03:34:10Z |
Reply
|
Hsu C.; PEI-JER CHEN; Cheng A.-L. |
| 臺大學術典藏 |
2021-07-03T03:34:10Z |
Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study
|
Hsu C.; Tsou H.-H.; Lin S.-J.; Wang M.-C.; Yao M.; Hwang W.-L.; Kao W.-Y.; Chiu C.-F.; Lin S.-F.; Lin J.; Chang C.-S.; Tien H.-F.; Liu T.-W.; PEI-JER CHEN; Cheng A.-L. |
| 臺大學術典藏 |
2021-07-03T03:33:36Z |
Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection
|
Yang H.-C.; Tsou H.-H.; Pei S.-N.; Chang C.-S.; Chen J.-H.; Yao M.; Lin S.-J.; Lin J.; Yuan Q.; Xia N.; Liu T.-W.; PEI-JER CHEN; Cheng A.-L.; Hsu C.; Taiwan Cooperative Oncology Group |
| 臺大學術典藏 |
2021-07-03T03:33:29Z |
Cost-effectiveness of preventing hepatitis B virus reactivation in patients with lymphoma and resolved HBV infection
|
Tsou H.-H.; Yang H.-C.; Hsiao C.-F.; Hsiung C.A.; Liu T.-W.; Chuang M.-H.; Wu H.-Y.; Hsu Y.-T.; Tsui C.-W.; PEI-JER CHEN; Cheng A.-L.; Hsu C.; Taiwan Cooperative Oncology Group |
| 國家衛生研究院 |
2021-07 |
A phase I study of biweekly abraxane in combination with oxaliplatin and oral S-1/leucovorin as first line treatment for advanced gastric, pancreatic and biliary tract cancers
|
Tsai, H;Yang, S;Hsiao, C;Kao, H;Shan, Y;Lin, Y;Yen, C;Du, J;Hsu, C;Wu, I;Chen, L |
| 國家衛生研究院 |
2021-07 |
Nivolumab plus ipilimumab as neoadjuvant therapy for potentially resectable hepatocellular carcinoma
|
Su, Y;Lin, Y;Hsiao, C;Ou, D;Chen, S;Wu, Y;Lee, W;Lin, J;Hsu, C;Ho, M;Lu, L;Wu, T;Lai, S;Chao, Y;Chou, T;Yen, C;Chen, L;Shan, Y;Cheng, A;Hsu, C |
| 國家衛生研究院 |
2021-07 |
Atezolizumab plus bevacizumab for patients with advanced hepatocellular carcinoma and chronic hepatitis B virus infection with high viral load
|
Chen, S;Lai, H;Tsou, H;Shao, Y;Chang, C;Su, T;Liu, T;Chen, L;Cheng, A;Hsu, C |
| 臺大學術典藏 |
2021-06-15T03:12:22Z |
Expression of the caudal-type homeodomain transcription factor CDX2 is related to clinical outcome in biliary tract carcinoma
|
Chang Y.-T.; Hsu C.; Jeng Y.-M.; Chang M.-C.; SHU-CHEN WEI; Wong J.-M. |
| 臺大學術典藏 |
2021-06-15T03:12:18Z |
Serum vascular endothelial growth factor/soluble vascular endothelial growth factor receptor 1 ratio is an independent prognostic marker in pancreatic cancer
|
Chang Y.-T.; Chang M.-C.; SHU-CHEN WEI; Tien Y.-W.; Hsu C.; Liang P.-C.; Tsao P.-N.; Jan I.-S.; Wong J.-M. |
| 臺大學術典藏 |
2021-06-15T03:12:17Z |
Strategies to prevent hepatitis B virus reactivation in patients receiving immunosuppressive therapy
|
Hsu C.; SHU-CHEN WEI; Cheng A.-L.; Chen P.-J. |
| 國家衛生研究院 |
2021-06-15 |
Adjuvant versus neoadjuvant immunotherapy for hepatocellular carcinoma: Clinical and immunologic perspectives
|
Su, YY;Li, CC;Lin, YJ;Hsu, C |
| 臺大學術典藏 |
2021-06-09T08:12:22Z |
Critical Trio Exome Benefits In-Time Decision-Making for Pediatric Patients with Severe Illnesses?
|
Wu E.-T.;Wuh-Liang Hwu;Chien Y.-H.;Hsu C.;Chen T.-F.;Chen N.-Q.;Chou H.-C.;Tsao P.-N.;Fan P.-C.;Tsai I.-J.;Lin S.-P.;Hsieh W.-S.;Chang T.-M.;Chen C.-N.;Lee C.-H.;Chou Y.-Y.;Chiu P.-C.;Tsai W.-H.;Hsiung H.-C.;Lai F.;Lee N.-C.; Wu E.-T.; WUH-LIANG HWU; Chien Y.-H.; Hsu C.; Chen T.-F.; Chen N.-Q.; Chou H.-C.; Tsao P.-N.; Fan P.-C.; Tsai I.-J.; Lin S.-P.; Hsieh W.-S.; Chang T.-M.; Chen C.-N.; Lee C.-H.; Chou Y.-Y.; Chiu P.-C.; Tsai W.-H.; Hsiung H.-C.; Lai F.; Lee N.-C. |
| 臺大學術典藏 |
2021-06-09T08:12:19Z |
Frequency and spectrum of actionable pathogenic secondary findings in Taiwanese exomes
|
Kuo C.-W.;Wuh-Liang Hwu;Chien Y.-H.;Hsu C.;Hung M.-Z.;Lin I.-L.;Lai F.;Lee N.-C.; Kuo C.-W.; WUH-LIANG HWU; Chien Y.-H.; Hsu C.; Hung M.-Z.; Lin I.-L.; Lai F.; Lee N.-C. |
| 臺大學術典藏 |
2021-05-26T09:08:26Z |
MVP (mitomycin-C, vinblastine, cisplatin) salvage chemotherapy for relapsed and refractory metastatic breast cancer
|
Hsu C.; Yeh K.-H.; Hong R.-L.; Yang C.-H.; Lin M.-T.; YAO-CHANG CHEN; Cheng A.-L. |
| 臺大學術典藏 |
2021-05-26T09:08:22Z |
Allogeneic stem cell transplantation for patients with high-risk myelodysplastic syndrome
|
Hsu C.; Lin M.-T.; Tang J.-L.; Tien H.-F.; Wang C.-H.; YAO-CHANG CHEN |
| 臺大學術典藏 |
2021-05-26T09:08:21Z |
Chemotherapy alone versus, surgery followed by chemotherapy for stage I/IIE large-cell lymphoma of the stomach
|
Liu H.-T.; Hsu C.; Chen C.-L.; Chiang I.-P.; Chen L.-T.; YAO-CHANG CHEN; Cheng A.-L. |
| 臺大學術典藏 |
2021-05-26T09:08:20Z |
Comparison of MALT and non-MALT primary large cell lymphoma of the stomach: Does histologic evidence of MALT affect chemotherapy response?
|
Hsu C.; Chen C.-L.; Chen L.-T.; Liu H.-T.; YAO-CHANG CHEN; Jan C.-M.; Liu C.-S.; Cheng A.-L. |
| 臺大學術典藏 |
2021-05-26T09:08:17Z |
Survival-weighted health profile for long-term survivors of acute myelogenous leukemia
|
Hsu C.; Wang J.-D.; Hwang J.-S.; Tien H.-F.; Chang S.-M.; Cheng A.-L.; YAO-CHANG CHEN; Tang J.-L. |
| 臺大學術典藏 |
2021-05-26T09:08:10Z |
Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-/hypercellular MDS by International Prognostic Scoring System, cytogenetic and genetic studies
|
Huang T.-C.; Ko B.-S.; Tang J.-L.; Hsu C.; Chen C.-Y.; Tsay W.; Huang S.-Y.; Yao M.; YAO-CHANG CHEN; Shen M.-C.; Wang C.-H.; Tien H.-F. |
| 臺大學術典藏 |
2021-05-26T09:08:03Z |
Overexpression of 14-3-3ε predicts tumour metastasis and poor survival in hepatocellular carcinoma
|
Ko B.-S.; Chang T.-C.; Hsu C.; YAO-CHANG CHEN; Shen T.-L.; Chen S.-C.; Wang J.; Wu K.K.; Jan Y.-J.; Liou J.-Y. |
| 臺大學術典藏 |
2021-05-26T03:35:12Z |
Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer
|
Yang C.H.; Tsai C.M.; Wang L.S.; Lee Y.C.; Chang C.J.; Lui L.T.; Yen S.H.; Hsu C.; Cheng A.L.; Liu M.Y.; Chiang S.C.; Chen Y.M.; KWEN-TAY LUH; Huang M.H.; Yang P.-C.; Perng R.-P. |
| 臺大學術典藏 |
2021-05-25T06:35:57Z |
Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-/hypercellular MDS by International Prognostic Scoring System, cytogenetic and genetic studies
|
Huang T.-C.; Ko B.-S.; Tang J.-L.; Hsu C.; Chen C.-Y.; Tsay W.; Huang S.-Y.; Yao M.; Chen Y.-C.; MING-CHING SHEN; Wang C.-H.; Tien H.-F. |
| 臺大學術典藏 |
2021-05-18T08:25:10Z |
Isolation of individual isoflavone species from soybean by solvent extraction followed by the combination of macroporous resin and aluminium oxide separation
|
Hsu, C.;Wang, S.-T.;Wu, B.-Y.;Hung, Y.-T.;Su, N.-W.; Hsu, C.; Wang, S.-T.; Wu, B.-Y.; Hung, Y.-T.; Su, N.-W.; NAN-WEI SU |
| 臺大學術典藏 |
2021-05-18T08:25:10Z |
Osteoprotective effect of genistein 7-O-phosphate, a derivative of genistein with high bioavailability, in ovariectomized rats
|
Wang, S.-T.;Chang, H.-S.;Hsu, C.;Su, N.-W.; Wang, S.-T.; Chang, H.-S.; Hsu, C.; Su, N.-W.; NAN-WEI SU |
| 國家衛生研究院 |
2021-05-12 |
Exploring markers of exhausted CD8 T cells to predict response to immune checkpoint inhibitor therapy for hepatocellular carcinoma
|
Hsu, CL;Ou, DL;Bai, LY;Chen, CW;Lin, L;Huang, SF;Cheng, AL;Jeng, YM;Hsu, C |
| 臺大學術典藏 |
2021-05-06T01:52:13Z |
Chlorhexidine for the prevention of bloodstream infection associated with totally implantable venous ports in patients with solid cancers
|
Kao H.-F.; Chen I.-C.; Hsu C.; Chang S.-Y.; Chien S.-F.; YEE-CHUN CHEN; Hu F.-C.; Yang J.C.-H.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2021-04-27T08:36:02Z |
The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia
|
HUNG-YANG KUO; Lin Z.-Z.; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; Shao Y.-Y.; Hsu C.; Cheng W.-F.; Cheng A.-L.; Yang J.C.H.; Lai M.-S. |
| 臺大學術典藏 |
2021-04-27T08:11:51Z |
The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia
|
HUNG-YANG KUO; Lin Z.-Z.; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; Shao Y.-Y.; Hsu C.; Cheng W.-F.; Cheng A.-L.; Yang J.C.H.; Lai M.-S. |
| 臺大學術典藏 |
2021-04-26T01:47:25Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; MING-CHIH HO; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2021-04-22T06:56:51Z |
Low-dose thalidomide treatment for advanced hepatocellular carcinoma
|
Hsu C.; Chen C.-N.; Chen L.-T.; Wu C.-Y.; PEI-MING YANG; Lai M.-Y.; Lee P.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-29T06:37:04Z |
Critical Trio Exome Benefits In-Time Decision-Making for Pediatric Patients with Severe Illnesses?
|
Wu, E.-T.; Hwu, W.-L.; Chien, Y.-H.; Hsu, C.; Chen, T.-F.; Chen, N.-Q.; Chou, H.-C.; Tsao, P.-N.; Fan, P.-C.; Tsai, I.-J.; Lin, S.-P.; Hsieh, W.-S.; Chang, T.-M.; Chen, C.-N.; Lee, C.-H.; Chou, Y.-Y.; Chiu, P.-C.; Tsai, W.-H.; Hsiung, H.-C.; Lai, F.; Lee, N.-C.; FEI-PEI LAI |
| 臺大學術典藏 |
2021-03-19T06:57:53Z |
Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment
|
Lin Z.-Z.; Hsu C.; YEUN-CHUNG CHANG; Yu C.-J.; Hsu C.-H.; Lin C.-C.; Cheng A.-L.; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2021-03-19T01:54:20Z |
Considerations of heterogeneity in clinical trials for hepatocellular carcinoma
|
TSUNG-HAO LIU; Shao Y.-Y.; Lu L.-C.; Shen Y.-C.; Hsu C.; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-19T01:54:19Z |
Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma
|
Shao Y.-Y.; TSUNG-HAO LIU; Hsu C.; Lu L.-C.; Shen Y.-C.; Lin Z.-Z.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2021-03-19T01:54:19Z |
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
|
Lu L.-C.; Hsu C.; Shao Y.-Y.; Chao Y.; Yen C.-J.; Shih I.-L.; Hung Y.-P.; Chang C.-J.; Shen Y.-C.; Guo J.-C.; TSUNG-HAO LIU; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-19T01:54:18Z |
Novel systemic therapy for hepatocellular carcinoma
|
Dong Y.; TSUNG-HAO LIU; Yau T.; Hsu C. |
| 臺大學術典藏 |
2021-03-18T08:54:39Z |
Diagnostic value of 18F-FDG-PET/CT in indeterminate infiltrative hepatic lesions in an endemic area of viral hepatitis
|
Cheng M.-F.; YEN-WEN WU; Liu K.-L.; Yen R.-F.; Wu Y.-M.; Hsu C.; Chang Y.-T.; Tzen K.-Y.; Wang H.-P. |
| 臺大學術典藏 |
2021-03-18T05:59:10Z |
Diagnostic value of 18F-FDG-PET/CT in indeterminate infiltrative hepatic lesions in an endemic area of viral hepatitis
|
Cheng M.-F.; Wu Y.-W.; Liu K.-L.; Yen R.-F.; Wu Y.-M.; Hsu C.; Chang Y.-T.; KAI-YUAN TZEN; Wang H.-P. |
| 臺大學術典藏 |
2021-03-18T03:23:39Z |
The first two lines of chemotherapy for anthracycline-naive metastatic breast cancer: A comparative study of the efficacy of anthracyclines and non-anthracyclines
|
WEI-WU CHEN; Chang D.-Y.; Huang S.-M.; Lin C.-H.; Hsu C.; Lin M.-H.; Huang C.-S.; Lu Y.-S.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-18T03:23:29Z |
Spectrum of cancer patients receiving renal biopsy
|
Chang F.-C.; WEI-WU CHEN; Huang T.T.-M.; Lin W.-C.; Liu J.-S.; Chiang W.-C.; Chen Y.-M.; Hsu C.; Yeh K.-H.; Chu T.-S. |
| 臺大學術典藏 |
2021-03-18T02:02:48Z |
Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study
|
Hsu C.-H.;Kang Y.K.;Yang T.-S.;Chia-Tung Shun;Shao Y.-Y.;Su W.-C.;Sandoval-Tan J.;Chiou T.-J.;Jin K.;Hsu C.;Cheng A.-L.; Hsu C.-H.; Kang Y.K.; Yang T.-S.; CHIA-TUNG SHUN; Shao Y.-Y.; Su W.-C.; Sandoval-Tan J.; Chiou T.-J.; Jin K.; Hsu C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-15T07:44:49Z |
Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer
|
LI-CHUN LU; Shao Y.-Y.; Hsu C.-H.; Hsu C.; Cheng W.-F.; Lin Y.-L.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2021-03-15T07:44:49Z |
Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems
|
Shao Y.-Y.; LI-CHUN LU; Lin Z.-Z.; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-15T07:44:46Z |
Tumor heterogeneity in hepatocellular carcinoma: Facing the challenges
|
LI-CHUN LU; Hsu C.-H.; Hsu C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-15T07:44:44Z |
Considerations of heterogeneity in clinical trials for hepatocellular carcinoma
|
Liu T.-H.;Shao Y.-Y.;Li-Chun Lu;Shen Y.-C.;Hsu C.;Lin Z.-Z.;Hsu C.-H.;Cheng A.-L.; Liu T.-H.; Shao Y.-Y.; LI-CHUN LU; Shen Y.-C.; Hsu C.; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-15T07:44:43Z |
Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma
|
Shao Y.-Y.;Liu T.-H.;Hsu C.;Li-Chun Lu;Shen Y.-C.;Lin Z.-Z.;Cheng A.-L.;Hsu C.-H.; Shao Y.-Y.; Liu T.-H.; Hsu C.; LI-CHUN LU; Shen Y.-C.; Lin Z.-Z.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2021-03-15T07:44:43Z |
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
|
Li-Chun Lu;Hsu C.;Shao Y.-Y.;Chao Y.;Yen C.-J.;Shih I.-L.;Hung Y.-P.;Chang C.-J.;Shen Y.-C.;Guo J.-C.;Liu T.-H.;Hsu C.-H.;Cheng A.-L.; LI-CHUN LU; Hsu C.; Shao Y.-Y.; Chao Y.; Yen C.-J.; Shih I.-L.; Hung Y.-P.; Chang C.-J.; Shen Y.-C.; Guo J.-C.; Liu T.-H.; Hsu C.-H.; Cheng A.-L. |
